Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;102:e73-e86

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simons, M.
Right arrow Articles by Rosengart, T. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simons, M.
Right arrow Articles by Rosengart, T. K.
Related Collections
Right arrow Angiogenesis
Right arrow Other Treatment
Right arrow Chronic ischemic heart disease

(Circulation. 2000;102:e73.)
© 2000 American Heart Association, Inc.


Current Perspective

Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus

An Expert Panel Summary

Michael Simons, MD; Robert O. Bonow, MD; Nicolas A. Chronos, MD; David J. Cohen, MD, MSc; Frank J. Giordano, MD; H. Kirk Hammond, MD; Roger J. Laham, MD; William Li, MD; Marylin Pike, MD; Frank W. Sellke, MD; Thomas J. Stegmann, MD; James E. Udelson, MD; Todd K. Rosengart, MD

From the Angiogenesis Research Center (M.S., R.J.L., F.W.S.), Interventional Cardiology (D.J.C., R.J.L.) and Division of Cardiothoracic Surgery (F.W.S.), BIDMC, Harvard Medical School, Boston, Mass; Division of Cardiology, Northwestern University School of Medicine (R.O.B.), Chicago, Ill; Atlanta Cardiology (N.A.C.), Atlanta, Ga; Division of Cardiology, Yale University School of Medicine (F.J.G.), New Haven, Conn; VA Medical Center and University of California-San Diego (H.K.H.), San Diego, Calif; The Angiogenesis Foundation (W.L.), Cambridge, Mass; Chiron Corporation (M.P.), Sunnyvale, Calif; Department of Thoracic and Cardiovascular Surgery, Fulda Hospital (T.J.S.), Fulda, Germany; Division of Cardiology, New England Medical Center and Tufts University School of Medicine (J.E.U.), Boston, Mass; and Division of Cardiothoracic Surgery, Evanston Hospital, Northwestern University (T.K.R.), Chicago, Ill.

Correspondence to Michael Simons, MD, Angiogenesis Research Center, SL-423, BIDMC, 330 Brookline Ave, Boston, MA 02215. E-mail msimons{at}caregroup.harvard.edu

Abstract—The rapid development of angiogenic growth factor therapy for patients with advanced ischemic heart disease over the last 5 years offers hope of a new treatment strategy based on generation of new blood supply in the diseased heart. However, as the field of therapeutic coronary angiogenesis is maturing from basic and preclinical investigations to clinical trials, many new and presently unresolved issues are coming into focus. These include in-depth understanding of the biology of angiogenesis, selection of appropriate patient populations for clinical trials, choice of therapeutic end points and means of their assessment, choice of therapeutic strategy (gene versus protein delivery), route of administration, and the side effect profile. The present article presents a summary statement of a panel of experts actively working in the field, convened by the Angiogenesis Foundation and the Angiogenesis Research Center during the 72nd meeting of the American Heart Association to define and achieve a consensus on the challenges facing development of therapeutic angiogenesis for coronary disease.


Key Words: angiogenesis • coronary disease • growth substances • revascularization • clinical trials




This article has been cited by other articles:


Home page
J. Thorac. Cardiovasc. Surg.Home page
C. S. Sarateanu, M. A. Retuerto, J. T. Beckmann, L. McGregor, J. Carbray, G. Patejunas, L. Nayak, J. Milbrandt, and T. K. Rosengart
An Egr-1 master switch for arteriogenesis: Studies in Egr-1 homozygous negative and wild-type animals
J. Thorac. Cardiovasc. Surg., January 1, 2006; 131(1): 138 - 145.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Hou, E. A.-S. Youssef, T. J. Brinton, P. Zhang, P. Rogers, E. T. Price, A. C. Yeung, B. H. Johnstone, P. G. Yock, and K. L. March
Radiolabeled Cell Distribution After Intramyocardial, Intracoronary, and Interstitial Retrograde Coronary Venous Delivery: Implications for Current Clinical Trials
Circulation, August 30, 2005; 112(9_suppl): I-150 - I-156.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
M. Komori, Y. Tomizawa, K. Takada, and M. Ozaki
A Single Local Application of Recombinant Human Basic Fibroblast Growth Factor Accelerates Initial Angiogenesis During Wound Healing in Rabbit Ear Chamber
Anesth. Analg., March 1, 2005; 100(3): 830 - 834.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. V. Simoes, M. Miyagawa, S. Reder, C. Stadele, R. Haubner, W. Linke, T. Lehner, P. Epple, M. Anton, M. Schwaiger, et al.
Myocardial Kinetics of Reporter Probe 124I-FIAU in Isolated Perfused Rat Hearts After In Vivo Adenoviral Transfer of Herpes Simplex Virus Type 1 Thymidine Kinase Reporter Gene
J. Nucl. Med., January 1, 2005; 46(1): 98 - 105.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. A. Retuerto, P. Schalch, G. Patejunas, J. Carbray, N. Liu, K. Esser, R. G. Crystal, and T. K. Rosengart
Angiogenic pretreatment improves the efficacy of cellular cardiomyoplasty performed with fetal cardiomyocyte implantation
J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1041 - 1050.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
M Fujita and K Tambara
Recent insights into human coronary collateral development
Heart, March 1, 2004; 90(3): 246 - 250.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Rajagopalan, E. R. Mohler III, R. J. Lederman, F. O. Mendelsohn, J. F. Saucedo, C. K. Goldman, J. Blebea, J. Macko, P. D. Kessler, H. S. Rasmussen, et al.
Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial Disease: A Phase II Randomized, Double-Blind, Controlled Study of Adenoviral Delivery of Vascular Endothelial Growth Factor 121 in Patients With Disabling Intermittent Claudication
Circulation, September 22, 2003; (2003) 100000933981612429.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
W. Poller, H. Fechner, M. Noutsias, C. Tschoepe, M. Pauschinger, and H.-P. Schultheiss
The molecular basis of cardiotropic viral infections
Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I18 - I30.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
P Menasche and M Desnos
Cardiac reparation: fixing the heart with cells, new vessels and genes
Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D73 - D81.
[Abstract] [PDF]


Home page
HypertensionHome page
R. Khurana, J. F. Martin, and I. Zachary
Gene Therapy for Cardiovascular Disease: A Case for Cautious Optimism
Hypertension, November 1, 2001; 38(5): 1210 - 1216.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Z. S. Kyriakides, D. T. Kremastinos, P. Karayannakos, L. H. W. Gowdak, L. Poliakova, X. Wang, E. G. Lakatta, M. Talan, K. W. Fishbein, R. G.S. Spencer, et al.
Estrogen Stimulates Angiogenesis in Normoperfused Skeletal Muscle in Rabbits Response
Circulation, May 29, 2001; 103 (21): e107 - e108.
[Full Text] [PDF]


Home page
CirculationHome page
T. Matsunaga, D. W. Weihrauch, M. C. Moniz, J. Tessmer, D. C. Warltier, and W. M. Chilian
Angiostatin Inhibits Coronary Angiogenesis During Impaired Production of Nitric Oxide
Circulation, May 7, 2002; 105(18): 2185 - 2191.
[Abstract] [Full Text] [PDF]